Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LPX-TI641 in Healthy Volunteers
NCT05853835Phase 1Completed
- Sponsor
- LAPIX Therapeutics
- Start
- Oct 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of lpx-ti641 in multiple sclerosis (MS) and autoimmune diseases (9 cohorts), sponsored by LAPIX Therapeutics. Primary endpoints: Safety and tolerability after single ascending oral doses at 14 days and Safety and tolerability after multiple ascending oral doses at 21 days. Started Oct 2023; status: completed.
02
Drugs
lpx-ti641
03
Conditions
multiple sclerosis (MS)autoimmune diseases
Beyond the preview
Go deeper on NCT05853835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05853835.